General Information of Drug (ID: DMZLGRB)

Drug Name
Pimecrolimus Drug Info
Synonyms Elidel; ASM 981; SDZ ASM 981; ASM-981; ASM-998; Elidel (TN); SDZ-ASM 981; Pimecrolimus [USAN:INN:BAN]; SDZ-ASM-981; Pimecrolimus (JAN/USAN/INN); 33-epi-Chloro-33-desoxyascomycin
Indication
Disease Entry ICD 11 Status REF
Atopic dermatitis EA80 Approved [1]
Therapeutic Class
Dermatologic Agents
Cross-matching ID
PubChem CID
6509979
ChEBI ID
CHEBI:135888
CAS Number
CAS 137071-32-0
TTD Drug ID
DMZLGRB
INTEDE Drug ID
DR1289

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Calcineurin (PPP3CA) TTA4LDE PP2BA_HUMAN Inhibitor [2]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID Highest Status REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Approved [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Calcineurin (PPP3CA) DTT PPP3CA 6.282 7.43 6.685 6.815
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 11.692 6.58 4.984 9.089
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Atopic dermatitis
ICD Disease Classification EA80
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Calcineurin (PPP3CA) DTT PPP3CA 5.29E-01 1.74E-03 9.99E-03
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 8.67E-01 -3.83E-03 -1.24E-02
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6783).
2 Treatment of chronic blepharokeratoconjunctivitis with local calcineurin inhibitors. Ophthalmologe. 2009 Jul;106(7):635-8.
3 Pimecrolimus: absorption, distribution, metabolism, and excretion in healthy volunteers after a single oral dose and supplementary investigations in vitro. Drug Metab Dispos. 2006 May;34(5):765-74.